Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Clin Exp Rheumatol ; 36(1): 136-139, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-28850025

RESUMO

OBJECTIVES: Monoclonal antibodies are important in the treatment of rheumatoid arthritis (RA). This is the first trial to monitor the effect of adalimumab dose escalation in persistently active RA. The aim of this study was to identify the response to adalimumab to improve the basis for making decision in relation to actual drug capacity in serum. METHODS: The disease activity of RA patients was assessed with CDAI and DAS28 before administration of additional 40 mg adalimumab one week after standard injection. Serum samples were analysed using the recoveryELISA technology, a combination of sandwich ELISA and competitive assay. The recoveryELISA measure the concentrations of free TNF-α, drug level, and the remaining active adalimumab in the patients' sera. An adalimumab concentration of 5.0-10.0 g/mL was defined as the targeted therapeutic window. RESULTS: Five of 8 patients achieved moderate EULAR response by dose escalation. The results of the free adalimumab and TNF-α neutralisation measurements allowed a separation of the cohort (n=17) into three groups. Group 1 represents 18% of the patients with free adalimumab level higher 30.0 µg/mL and TNF-α neutralisation above 95%. Group 2 (47%) consists of patients within the therapeutic window with balanced free adalimumab and TNF-α neutralisation values. Group 3 contains 35% of the cohort with low concentrations of free adalimumab and lowest remaining TNF-α-neutralisation capacity. Anti-drug antibodies were detected in four patients but did not prevent response to treatment. CONCLUSIONS: Drug and antigen monitoring using recoveryELISA may support dose decision to avoid unnecessary switch in medication or possible overtreatment.


Assuntos
Adalimumab/administração & dosagem , Antirreumáticos/administração & dosagem , Artrite Reumatoide/tratamento farmacológico , Monitoramento de Medicamentos/métodos , Ensaio de Imunoadsorção Enzimática , Adalimumab/efeitos adversos , Adalimumab/sangue , Adulto , Idoso , Antirreumáticos/efeitos adversos , Antirreumáticos/sangue , Artrite Reumatoide/diagnóstico , Artrite Reumatoide/imunologia , Cálculos da Dosagem de Medicamento , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Estudo de Prova de Conceito , Fatores de Tempo , Resultado do Tratamento , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Fator de Necrose Tumoral alfa/sangue , Fator de Necrose Tumoral alfa/imunologia
2.
EMBO J ; 31(17): 3635-46, 2012 Aug 29.
Artigo em Inglês | MEDLINE | ID: mdl-22850675

RESUMO

Stomatin proteins oligomerize at membranes and have been implicated in ion channel regulation and membrane trafficking. To obtain mechanistic insights into their function, we determined three crystal structures of the conserved stomatin domain of mouse stomatin that assembles into a banana-shaped dimer. We show that dimerization is crucial for the repression of acid-sensing ion channel 3 (ASIC3) activity. A hydrophobic pocket at the inside of the concave surface is open in the presence of an internal peptide ligand and closes in the absence of this ligand, and we demonstrate a function of this pocket in the inhibition of ASIC3 activity. In one crystal form, stomatin assembles via two conserved surfaces into a cylindrical oligomer, and these oligomerization surfaces are also essential for the inhibition of ASIC3-mediated currents. The assembly mode of stomatin uncovered in this study might serve as a model to understand oligomerization processes of related membrane-remodelling proteins, such as flotillin and prohibitin.


Assuntos
Canais Iônicos Sensíveis a Ácido/metabolismo , Proteínas Sanguíneas/metabolismo , Proteínas de Membrana/metabolismo , Canais Iônicos Sensíveis a Ácido/química , Animais , Proteínas Sanguíneas/química , Proteínas Sanguíneas/genética , Células CHO , Células Cultivadas , Cricetinae , Cricetulus , Dimerização , Fibroblastos , Células HEK293 , Humanos , Proteínas de Membrana/química , Proteínas de Membrana/genética , Camundongos , Camundongos Transgênicos , Estrutura Terciária de Proteína , Ratos
4.
FASEB J ; 23(2): 483-91, 2009 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18927250

RESUMO

The small GTPase Rab5 is a key regulator of endosome/phagosome maturation and in intravesicular infections marks a phagosome stage at which decisions over pathogen replication or destruction are integrated. It is currently unclear whether Leishmania-infected phagosomes uniformly pass through a Rab5(+) stage on their intracellular path to compartments with late endosomal/early lysosomal characteristics. Differences in routes and final compartments could have consequences for accessibility to antileishmanial drugs. Here, we generated a unique gfp-rab5 transgenic mouse model to visualize Rab5 recruitment to early parasite-containing phagosomes in primary host cells. Using real-time fluorescence imaging of phagosomes carrying Leishmania mexicana, we determined that parasite-infested phagosomes follow a uniform sequence of transient Rab5 recruitment. Residence in Rab5(+) compartments was much shorter compared with phagosomes harboring latex beads. Furthermore, a comparative analysis of parasite life-cycle stages and mutants deficient in lpg1, the gene encoding the enzyme required for synthesis of the dominant surface lipophosphoglycan, indicated that parasite surface ligands and host cell receptors modulate pathogen residence times in Rab5(+) phagosomes, but, as far as tested, had no significant effect on intracellular L. mexicana survival or replication.


Assuntos
Leishmania mexicana/fisiologia , Macrófagos/metabolismo , Fagossomos/metabolismo , Proteínas rab5 de Ligação ao GTP/metabolismo , Animais , Células Cultivadas , Feminino , Proteínas de Fluorescência Verde/metabolismo , Cinética , Ligantes , Camundongos , Camundongos Transgênicos , Fatores de Tempo , Transgenes/genética , Proteínas rab5 de Ligação ao GTP/genética
5.
Mol Oncol ; 9(7): 1348-58, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-25953704

RESUMO

Multiple myeloma (MM) is an aggressive incurable plasma cell malignancy with a median life expectancy of less than seven years. Antibody-based therapies have demonstrated substantial clinical benefit for patients with hematological malignancies, particular in B cell Non-Hodgkin's lymphoma. The lack of immunotherapies specifically targeting MM cells led us to develop a human-mouse chimeric antibody directed against the B cell maturation antigen (BCMA), which is almost exclusively expressed on plasma cells and multiple myeloma cells. The high affinity antibody blocks the binding of the native ligands APRIL and BAFF to BCMA. This finding is rationalized by the high resolution crystal structure of the Fab fragment in complex with the extracellular domain of BCMA. Most importantly, the antibody effectively depletes MM cells in vitro and in vivo and substantially prolongs tumor-free survival under therapeutic conditions in a xenograft mouse model. A BCMA-antibody-based therapy is therefore a promising option for the effective treatment of multiple myeloma and autoimmune diseases.


Assuntos
Antígeno de Maturação de Linfócitos B/imunologia , Mieloma Múltiplo/imunologia , Animais , Afinidade de Anticorpos , Modelos Animais de Doenças , Epitopos/imunologia , Feminino , Glicosilação , Camundongos , Camundongos Endogâmicos NOD , Camundongos SCID , NF-kappa B/metabolismo
6.
Eur J Cell Biol ; 91(4): 240-5, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21501885

RESUMO

The stomatin-domain defines a family of proteins that are found in all classes of life. The ubiquity of stomatin-family proteins and their high degree of homology suggest that they have a unifying cellular function, which has yet to be defined. The five stomatin family proteins in mammals show varying expression patterns and different sub-cellular distributions. In surveying the relevant literature, three common themes emerge; stomatin family members are oligomeric; they mostly localise to membrane domains; and in many cases, they have been shown to modulate ion channel activity. How oligomerisation and membrane localisation contribute to the modulation of channel function is unclear to date. Future studies into the precise structure and mechanism of stomatin-like proteins need to address these important questions to clarify the detailed cellular function of stomatin-domain containing proteins.


Assuntos
Proteínas Sanguíneas/química , Proteínas de Caenorhabditis elegans/química , Proteínas de Membrana/química , Proteínas do Tecido Nervoso/química , Homologia de Sequência de Aminoácidos , Animais , Proteínas Sanguíneas/genética , Proteínas de Caenorhabditis elegans/genética , Humanos , Líquido Intracelular/química , Líquido Intracelular/parasitologia , Proteínas de Membrana/deficiência , Proteínas de Membrana/genética , Camundongos , Camundongos Knockout , Proteínas do Tecido Nervoso/deficiência , Proteínas do Tecido Nervoso/genética , Estrutura Terciária de Proteína/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA